About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota June 11, 2018 By CKD Digital
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota
Ridinilazole Reduces Recurrence of Clostridium difficile Infection with Minimal Impact on the Gut Microbiota June 11, 2018 By CKD Digital
